Search
Returning search results with filters:
Remove filter for
Category: Biologic or vaccine
Remove filter for
Issue: New safety information
Remove filter for
Issue: COVID
Remove filter for
Last updated: 2022
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 3 of 3 items.
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
AlertHealth professional risk communication | 2022-10-26
Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omicron BA.2 Subvariant
AlertHealth professional risk communication | 2022-04-14
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
AlertHealth professional risk communication | 2022-01-07